Understanding and targeting resistance mechanisms in NSCLC

Key Points The spectrum of known and putative oncogenic drivers with companion targeted therapies continues to increase. As broader mutational testing becomes more clinically available, a greater proportion of patients with non-small-cell lung cancer (NSCLC) will be eligible for targeted therapies....

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Nature reviews. Cancer Ročník 17; číslo 11; s. 637 - 658
Hlavní autoři:	Rotow, Julia, Bivona, Trever G.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	London Nature Publishing Group UK 01.11.2017 Nature Publishing Group
Témata:	631/67/1059/2326 631/67/1059/602 631/67/1612/1350 AKT protein Animals Antineoplastic Agents - pharmacology Biomedicine Cancer Research Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Drug Resistance, Neoplasm - drug effects Epidermal growth factor Epidermal growth factor receptors Genetic aspects Humans Kinases Lung Neoplasms - drug therapy Lung Neoplasms - pathology Lymphoma Microbial drug resistance Mutation Non-small cell lung cancer Non-small cell lung carcinoma Protein-tyrosine kinase receptors Raf protein review-article Risk factors Signal transduction Threonine Tumor microenvironment Tumors
ISSN:	1474-175X, 1474-1768, 1474-1768
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!